BioSpace News Archive

Heska Corporation, a leading provider of advanced veterinary diagnostic and specialty products, reported financial results for its first quarter ended March 31, 2020.

Patents further protect company’s GoodWheat™ specialty wheat ingredients

Trastuzumab deruxtecan to receive expedited review by Japan MHLW based on SAKIGAKE designation for second potential indication in Japan

Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today it plans to release financial results for its fiscal 2020 second quarter ended March 31, 2020 after market close on Thursday, May 14, 2020. In conjunction with the release, the Company has scheduled a conference call at 4:30 p.m. Eastern Time that will also be broadcast live over the Internet. What: Applied DNA’s Fiscal 2020 Second Qu

Interim Three Month Top-line Biomarker Data Expected for the First 50% of Patients Enrolled in Phase 2 Osteoporosis Clinical Trial

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis announced today that it will host a

Danaher Corporation (NYSE:DHR) (“Danaher”) announced today that it has commenced concurrent offerings of $1.25 billion of shares of common stock and $1.25 billion of shares of Series B Mandatory Convertible Preferred Stock, subject to market and other conditions (the offerings). Danaher expects to grant the underwriters separate 30-day o

Preventice Solutions announced the publication of real-world data further validating BeatLogic® deep learning models designed to detect and classify multiple levels of data on heart rhythms gathered using BodyGuardian® remote cardiac monitoring technology.

Nearly two-thirds of school-aged children are bullied by their peers during their school years, according to new research published in the May issue of Pediatrics.

Latest Premier survey indicates that shortages of reagents and testing swabs are the main barriers to more widespread testing.